| CAS NO: | 208107-14-6 |
| 包装 | 价格(元) |
| 500 μg | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| Cas No. | 208107-14-6 |
| 别名 | 替莫唑胺 d3 |
| Canonical SMILES | O=C(N(C([2H])([2H])[2H])N=N1)N2C1=C(C(N)=O)N=C2 |
| 分子式 | C6H3D3N6O2 |
| 分子量 | 197.2 |
| 溶解度 | DMF: 5 mg/ml,DMSO: 5 mg/ml,PBS (pH 7.2): 0.33 mg/ml |
| 储存条件 | Store at 2°C to 8°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Temozolomide-d3(TMZ-d3) contains three deuterium atoms located on the methyl group. It is intended for use as an internal standard for the quantification of temozolomide by GC- or LC-MS. TMZ is an imidazotetrazine that is converted to a compound capable of alkylating DNA, thus interfering with DNA replication and leading to cytotoxicity in proliferating cells.1TMZ is rapidly and completely absorbed from the gastrointestinal tract after oral administration and readily crosses the blood-brain barrier.1Formulations containing TMZ are effective in a variety of types of cancer, including aggressive brain cancers.1,2,3 1.Marchesi, F., Turriziani, M., Tortorelli, G., et al.Triazene compounds: Mechanism of action and related DNA repair systemsPharmacol. Res.56(4)275-287(2007) 2.Khan, O.A., Ranson, M., Michael, M., et al.A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancerBr. J. Cancer98(10)1614-1618(2008) 3.Daniel, R.A., Rozanska, A.L., Mulligan, E.A., et al.Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699Br. J. Cancer103(10)1588-1596(2010) |
m.cnreagent.com